A Phase I Trial of the Combination of the PARP Inhibitor ABT-888 With Intraperitoneal Floxuridine (FUDR) in Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancers
Phase of Trial: Phase I
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Veliparib (Primary) ; Floxuridine
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Biomarker; Pharmacogenomic
- 17 Oct 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jun 2017.
- 04 Feb 2013 New source identified and integrated (Mayo Clinic, 12-004933).
- 04 Feb 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.